Day 1

Overcoming Bioavailability Challenges of Very Weak Acid for Oral Delivery –A Case Study of HCV Drug Dasabuvir


Shuang Chen, Ph.D.

Sr. Principal Research Scientist Solid State Chemistry, Process R&D

AbbVie

Engineering Prodrug Therapies for Infectious Disease and Cancer Therapies


Professor Patrick Stayton

Distinguished Career Professor, Director, Molecular Engineering & Sciences Institute

University of Washington

Amorphous Solid Dispersions (ASD) – Considerations in Product Development


Raman Iyer

Associate Director, Technical R&D

Novartis Pharmaceuticals Corp.

How Safe Are My Combination Products? Regulatory Strategy Lifecycle Management Considerations


James Wabby

Global Head, Regulatory Affairs (CoE), Emerging Technologies, Combination Products and Devices

AbbVie

The Dynamic, Motile and Deformative Properties of RNA Nanoparticles Lead to Efficient Tumor Vasculature Targeting , Fast Renal Excretion and Rapid Body Clearance


Professor Peixuan Guo

Sylvan Frank Endowed Chair in Pharmaceutics and Drug Delivery

The Ohio State University

Long-acting biologics: a steep climb


Puneet Tyagi

Associate Director, Dosage Form Design & Development, Biopharmaceuticals Development, R&D

AstraZeneca

The Evolving Paradigm of Post-Market Safety Reporting (PMSR) for Combination Products


Khaudeja Bano

Vice President Combination Product and Device Safety, Executive Medical Director

Amgen

Opportunity and Challenges with Large Volume Subcutaneous Drug Delivery


Ning Yu

Director & Head of Device Development

Biogen

Enhancing Patient-Centricity During Product Development


Casey Dean

Manager, Device Development

Tolmar

Patient-Centric Device Solutions for Subcutaneous Biopharmaceutical Delivery


Dr. Ingo Waschulewski

Business Development & Sales Manager

Gerresheimer AG

Developing an Oral Modified Release (MR) Formulation


Helen Baker

Director, Pharmaceutical Sciences

Quotient Sciences